Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Nanobiotix S.A.

< Previous 1 2 Next >
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Closing of Global Offering
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
From Nanobiotix S.A.
Via GlobeNewswire
Tickers NBTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.